Prevention of prostate cancer

Share this content:
Men with no signs of prostate cancer should talk to their provider about taking a 5a-reductase inhibitor (5-ARI) for seven years to ward off the disease. This is a key recommendation of a new joint guideline from the American Society of Clinical Oncology (ASCO) and the American Urological Association (AUA).

The 5-ARI agents reduce the level of dihydrotestosterone, a hormone that can contribute to the growth of prostate cancer. ASCO and AUA suggest that men without any signs of prostate cancer who have a prostate-specific antigen (PSA) level <3.0 and are screened regularly or plan to get yearly PSA tests speak to their clinician about the preventive therapy. Men who are already taking a 5-ARI for other conditions should consider continuing the treatment as a means of preventing the development of prostate cancer.

ASCO and AUA based their recommendations in part on results from the Prostate Cancer Prevention Trial, in which participants took a 5-ARI for one to seven years. Most of the men who took the drug to prevent the disease showed an overall relative risk reduction of approximately 25%.

The guideline was published online ahead of print in the Journal of Clinical Oncology (accessed April 17, 2009) and The Journal of Urology.
Loading links....

2017 Upcoming Meetings

Sign Up for Free e-newsletters